Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.49 |
| ▸ | NEK2 | P51955 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7874125 | 0.88 | CRBN (0.48) | CRBNNEK2DDB1 | |
| SCHEMBL8589067 | 0.84 | CRBN (0.48) | CRBNDDB1HTR2AHTR2CHTR2B | |
| SCHEMBL14215285 | 0.80 | NEK2 (0.42) | CRBNNEK2DDB1HTR2B | |
| SCHEMBL18194978 | 0.80 | NEK2 (0.42) | CRBNNEK2HTR2B | |
| SCHEMBL4141843 | 0.80 | HTR2A (0.46) | CRBNDDB1HTR2AHTR2CHTR2B | |
| SCHEMBL8775591 | 0.79 | — | — | |
| SCHEMBL23288598 | 0.79 | CRBN (0.49) | CRBNDDB1IDO1TDO2 | |
| SCHEMBL20820896 | 0.79 | CRBN (0.49) | CRBNDDB1IDO1TDO2 | |
| SCHEMBL16182200 | 0.79 | CRBN (0.49) | CRBNDDB1IDO1TDO2 | |
| SCHEMBL561526 | 0.79 | CRBN (0.45) | CRBNDDB1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12090146-B2 | Substituted-pyridinyl compounds and uses thereof | BIONOMICS LIMITED (AU) | 2024-09-17 | — | — | US | disclosed |
| EP-3853216-B1 | 3-[2-(PHENOXY)-4-PYRIDYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DYSFUNCTION AND CNS DISORDERS | BIONOMICS LTD (AU) | 2024-09-11 | — | — | EP | disclosed |
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| EP-3743421-B1 | COMPOUNDS | UNIV OXFORD INNOVATION LTD (GB) | 2023-03-29 | — | — | EP | disclosed |
| WO-2023023534-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022258622-A1 | COMBINATION TREATMENT OF CANCER | ARES TRADING S.A. (CH) | 2022-12-15 | — | — | WO | disclosed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| US-20070232586-A1 | Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof | OHMOTO KAZUYUKI | 2007-10-04 | — | — | US | disclosed |
| EP-1739081-A1 | HYDRAZINO-SUBSTITUTED HETEROCYCLIC NITRILE COMPOUNDS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-03 | — | — | EP | disclosed |
| WO-2000027790-A1 | MUTILIN COMPOUNDS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-05-18 | — | — | WO | disclosed |
| EP-0452101-B1 | Spiro bridged and unbridged heterocyclic compounds | ISRAEL INST BIOLOG RES (IL) | 1999-07-07 | — | — | EP | disclosed |
| US-5852029-A | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1998-12-22 | — | — | US | disclosed |
| US-5534520-A | Spiro compounds containing five-membered rings | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1996-07-09 | — | — | US | disclosed |
| EP-0711292-A1 | AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY | KOSMIN, Gerald, Emmanuel (GB) | 1996-05-15 | — | — | EP | disclosed |
| US-5407938-A | Treating central nervous system disorders; Alzheimer*s | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1995-04-18 | — | — | US | disclosed |
| WO-1995003303-A2 | AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY | STATE OF ISRAEL, REPRESENTED BY THE PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1995-02-02 | — | — | WO | disclosed |
| EP-0452101-A2 | Spiro bridged and unbridged heterocyclic compounds | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | CRBN 4864/4885NEK2 4399/4885DDB1 4788/4885 |
| US-12090146-B2 | Substituted-pyridinyl compounds and uses thereof | GABRE, GAP43, GRIN2A | CRBN 588/4885NEK2 1285/4885DDB1 2930/4885 |
| US-20070232586-A1 | Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof | CTRL, PRSS1, CTSZ | CRBN 554/4885NEK2 1572/4885DDB1 3663/4885 |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | KRAS, NRAS, HRAS | CRBN 1604/4885NEK2 1363/4885DDB1 827/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | CRBN 3812/4885NEK2 2034/4885DDB1 4177/4885 |
| US-12024506-B2 | Compounds | KRAS, NRAS, HRAS | CRBN 2974/4885NEK2 1320/4885DDB1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.